Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:4852
Name pleomorphic xanthoastrocytoma
Definition A low grade glioma that is characterized by pleomorphic and lipidized cells expressing GFAP often surrounded by a reticulin network and eosinophilic granular bodies.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation benign neoplasm cell type benign neoplasm low grade glioma pleomorphic xanthoastrocytoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600E Dabrafenib + Trametinib pleomorphic xanthoastrocytoma sensitive detail...
BRAF V600E Vemurafenib pleomorphic xanthoastrocytoma predicted - sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib pleomorphic xanthoastrocytoma sensitive detail...
BRAF V600E Trametinib pleomorphic xanthoastrocytoma predicted - sensitive detail...
BRAF V600E Binimetinib + Ulixertinib pleomorphic xanthoastrocytoma sensitive detail...
BRAF V600E Selumetinib + Ulixertinib pleomorphic xanthoastrocytoma predicted - sensitive detail...
BRAF V600E Ulixertinib + Vinblastine pleomorphic xanthoastrocytoma sensitive detail...
BRAF V600E Trametinib + Ulixertinib pleomorphic xanthoastrocytoma predicted - sensitive detail...
BRAF V600E Navitoclax + Ulixertinib pleomorphic xanthoastrocytoma sensitive detail...
BRAF V600E Ulixertinib pleomorphic xanthoastrocytoma sensitive detail...
BRAF V600E PF-07799933 pleomorphic xanthoastrocytoma predicted - sensitive detail...
BRAF V600E Dabrafenib pleomorphic xanthoastrocytoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01837862 Phase Ib/II Carboplatin + Mebendazole + Temozolomide + Vincristine Sulfate Bevacizumab + Irinotecan + Mebendazole A Phase I/II Study of Mebendazole for the Treatment of Pediatric Gliomas Completed USA 0
NCT01999270 Phase I Bevacizumab + Irinotecan Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors Completed USA 0
NCT03919071 Phase II Dabrafenib + Trametinib Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma Recruiting USA 1
NCT03973918 Phase II Binimetinib + Encorafenib Study of Binimetinib With Encorafenib in Adults With Recurrent BRAF V600-Mutated HGG (BRAF) Terminated USA 0
NCT03975829 FDA approved Dabrafenib + Trametinib Pediatric Long-Term Follow-up and Rollover Study Active, not recruiting USA | SWE | NLD | ITA | ISR | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG 2
NCT04254419 Phase I Intra-tumoral Injection of Natural Killer Cells in High-Grade Gliomas Not yet recruiting USA 0
NCT04541082 Phase I ONC206 Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms Recruiting USA 0
NCT04923126 Phase Ib/II PD-0325901 SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma Recruiting USA 0
NCT05180825 Phase II Vinblastine Trametinib Pediatric Low Grade Glioma - MEKinhibitor TRIal vs Chemotherapy (PLGG - MEKTRIC) Recruiting FRA 0